Physician profile
Casey Scott Prough
NPI 1396723706
$615,033.44
in general payments reported to CMS, 2019-2025
40 companies · $109K in 2025
The $109K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64K · 2020: $35K · 2021: $61K · 2022: $116K · 2023: $111K · 2024: $119K · 2025: $109K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $305K · Food and Beverage: $14K · Travel and Lodging: $13K · Consulting Fee: $7,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $305,283.75 |
| Food and Beverage | $13,949.03 |
| Travel and Lodging | $12,695.71 |
| Consulting Fee | $7,300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $213,183.52 | 2020-2025 | Caplyta |
| Abbvie INC. | $182,108.53 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $126,512.58 | 2019-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Allergan, INC. | $58,111.73 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $12,799.09 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $8,722.29 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $4,450.52 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $1,193.98 | 2019-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $1,014.32 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $961.89 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $933.36 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Vanda Pharmaceuticals INC. | $794.18 | 2019-2025 | Fanapt, Hetlioz |
| Corium, LLC | $729.00 | 2021-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $523.64 | 2019-2024 | Trintellix |
| Supernus Pharmaceuticals, INC. | $477.72 | 2021-2025 | Qelbree, Qelbree |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $315.18 | 2019-2025 | Aplenzin, Wellbutrin |
| Merck Sharp & Dohme LLC | $306.82 | 2019-2023 | Belsomra |
| Axsome Therapeutics, INC. | $297.04 | 2022-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $185.41 | 2019-2024 | |
| Eisai INC. | $159.88 | 2020-2021 | |
| Adlon Therapeutics L.P. | $142.45 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $130.32 | 2022-2024 | Quviviq |
| Shire North American Group INC | $128.32 | 2019 | |
| Tris Pharma INC | $110.56 | 2023-2025 | Dyanavel Xr |
| Noven Therapeutics, LLC | $110.01 | 2020-2025 | Xelstrym, Secuado |
| Almatica Pharma LLC | $96.60 | 2021-2023 | Loreev Xr, Sertraline Hcl |
| Avanir Pharmaceuticals, INC. | $92.12 | 2020-2022 | |
| Harmony Biosciences LLC | $69.23 | 2023-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $66.88 | 2019-2021 | |
| Indivior INC. | $58.28 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $38.03 | 2020-2025 | Rejoyn |
| Biogen, INC. | $36.18 | 2021-2024 | |
| Arbor Pharmaceuticals, INC. | $35.21 | 2019-2020 | |
| Neuronetics, INC. | $33.60 | 2022-2023 | Neurostar Tms Therapy System |
| Vertical Pharmaceuticals, LLC | $30.23 | 2019-2020 | |
| Orexo US, INC. | $18.32 | 2019 | |
| Tonix Medicines, INC. | $16.97 | 2025 | Tonmya |
| Collegium Pharmaceutical, INC. | $13.80 | 2025 | Jornay Pm |
| Alfasigma USA, INC. | $13.41 | 2022 | |
| Neos Therapeutics, LP | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Prough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.